Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351632 | 0.91 | CNR2 (0.36) | PTGS2MAOAMAOBBACE1ALDH1A1 | |
| SCHEMBL352888 | 0.89 | MAOA (0.36) | PTGS2MAOAMAOBBACE1ALDH1A1 | |
| SCHEMBL352120 | 0.86 | MAOA (0.30) | MAOAMAOBALDH1A1HPGDHSD17B10 | |
| SCHEMBL10146335 | 0.80 | PTGS2 (0.36) | PTGS2ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL350815 | 0.78 | CNR2 (0.42) | MAOAMAOBALDH1A1MAPTCNR1 | |
| SCHEMBL351653 | 0.77 | HDAC1 (0.33) | PTGS2MAOAMAOBBACE1ALDH1A1 | |
| SCHEMBL352100 | 0.75 | BRD4 (0.48) | PTGS2MAOAMAOBGAAMAPT | |
| SCHEMBL352429 | 0.72 | CNR2 (0.34) | PTGS2ALDH1A1HPGDHSD17B10CNR1 | |
| SCHEMBL10147490 | 0.71 | — | — | |
| SCHEMBL350900 | 0.71 | PTGS2 (0.36) | PTGS2ALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015988-A1 | Sulfone Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, TRPV1 | PTGS2 263/4885MAOA 3696/4885MAOB 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.